249 related articles for article (PubMed ID: 21495716)
1. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells.
Kennedy AJ; Mathews TP; Kharel Y; Field SD; Moyer ML; East JE; Houck JD; Lynch KR; Macdonald TL
J Med Chem; 2011 May; 54(10):3524-48. PubMed ID: 21495716
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate.
Kharel Y; Raje M; Gao M; Gellett AM; Tomsig JL; Lynch KR; Santos WL
Biochem J; 2012 Oct; 447(1):149-57. PubMed ID: 22747486
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
Raje MR; Knott K; Kharel Y; Bissel P; Lynch KR; Santos WL
Bioorg Med Chem; 2012 Jan; 20(1):183-94. PubMed ID: 22137932
[TBL] [Abstract][Full Text] [Related]
4. Design of Sphingosine Kinases Inhibitors: Challenges and Recent Developments.
Magli E; Corvino A; Fiorino F; Frecentese F; Perissutti E; Saccone I; Santagada V; Caliendo G; Severino B
Curr Pharm Des; 2019; 25(9):956-968. PubMed ID: 30947653
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.
Kharel Y; Mathews TP; Gellett AM; Tomsig JL; Kennedy PC; Moyer ML; Macdonald TL; Lynch KR
Biochem J; 2011 Dec; 440(3):345-53. PubMed ID: 21848514
[TBL] [Abstract][Full Text] [Related]
6. Drugging sphingosine kinases.
Santos WL; Lynch KR
ACS Chem Biol; 2015 Jan; 10(1):225-33. PubMed ID: 25384187
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal.
Gude DR; Alvarez SE; Paugh SW; Mitra P; Yu J; Griffiths R; Barbour SE; Milstien S; Spiegel S
FASEB J; 2008 Aug; 22(8):2629-38. PubMed ID: 18362204
[TBL] [Abstract][Full Text] [Related]
8. Rational design of SphK inhibitors using crystal structures aided by computer.
Ding T; Zhi Y; Xie W; Yao Q; Liu B
Eur J Med Chem; 2021 Mar; 213():113164. PubMed ID: 33454547
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.
Evangelisti C; Evangelisti C; Buontempo F; Lonetti A; Orsini E; Chiarini F; Barata JT; Pyne S; Pyne NJ; Martelli AM
Leukemia; 2016 Nov; 30(11):2142-2151. PubMed ID: 27461062
[TBL] [Abstract][Full Text] [Related]
10. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
Paugh SW; Paugh BS; Rahmani M; Kapitonov D; Almenara JA; Kordula T; Milstien S; Adams JK; Zipkin RE; Grant S; Spiegel S
Blood; 2008 Aug; 112(4):1382-91. PubMed ID: 18511810
[TBL] [Abstract][Full Text] [Related]
11. Building a better sphingosine kinase-1 inhibitor.
Lynch KR
Biochem J; 2012 May; 444(1):e1-2. PubMed ID: 22533672
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine Kinase 2 Inhibition and Blood Sphingosine 1-Phosphate Levels.
Kharel Y; Morris EA; Congdon MD; Thorpe SB; Tomsig JL; Santos WL; Lynch KR
J Pharmacol Exp Ther; 2015 Oct; 355(1):23-31. PubMed ID: 26243740
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.
Schnute ME; McReynolds MD; Kasten T; Yates M; Jerome G; Rains JW; Hall T; Chrencik J; Kraus M; Cronin CN; Saabye M; Highkin MK; Broadus R; Ogawa S; Cukyne K; Zawadzke LE; Peterkin V; Iyanar K; Scholten JA; Wendling J; Fujiwara H; Nemirovskiy O; Wittwer AJ; Nagiec MM
Biochem J; 2012 May; 444(1):79-88. PubMed ID: 22397330
[TBL] [Abstract][Full Text] [Related]
14. Sphingosine kinase inhibitors: a review of patent literature (2006-2015).
Lynch KR; Thorpe SB; Santos WL
Expert Opin Ther Pat; 2016 Dec; 26(12):1409-1416. PubMed ID: 27539678
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells.
Gassowska M; Cieslik M; Wilkaniec A; Strosznajder JB
Neurochem Res; 2014 Apr; 39(4):645-52. PubMed ID: 24452756
[TBL] [Abstract][Full Text] [Related]
16. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling.
Edmonds Y; Milstien S; Spiegel S
Pharmacol Ther; 2011 Dec; 132(3):352-60. PubMed ID: 21906625
[TBL] [Abstract][Full Text] [Related]
17. Discovery, biological evaluation, and structure-activity relationship of amidine based sphingosine kinase inhibitors.
Mathews TP; Kennedy AJ; Kharel Y; Kennedy PC; Nicoara O; Sunkara M; Morris AJ; Wamhoff BR; Lynch KR; Macdonald TL
J Med Chem; 2010 Apr; 53(7):2766-78. PubMed ID: 20205392
[TBL] [Abstract][Full Text] [Related]
18. Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors.
Plano D; Amin S; Sharma AK
J Med Chem; 2014 Jul; 57(13):5509-24. PubMed ID: 24471412
[TBL] [Abstract][Full Text] [Related]
19. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
